Disease Modifying And Biologic Use For Covid 19 & The Cytokine Syndrome

Disease Modifying and Biologic Use for COVID 19 & the Cytokine Syndrome

Rutgers Robert Wood Johnson Department of Medicine

Rheumatology and Rehabilitation: COVID-19 and the use of rheumatology drugs

Royal Society of Medicine

COVID-19 Vaccine, Arthritis and Rheumatic Diseases

AlbertaRheumatology

Biologic use in the era of COVID-19

Dermatology Times

COVID 19, Rheumatic Diseases and Immunosuppressive Drugs by Dr. Humeira Badsha

Dr. Humeira Badsha

COVID-19 Vaccine, Arthritis and Rheumatic Diseases: Update

AlbertaRheumatology

COVID-19 Q&A Webinar

British Society for Rheumatology

Discussing Rheumatology: SELECT-PsA 2 and DMARDs in COVID-19

The Immune-Mediated Inflammatory Disease Forum

Antibodies, biologics and the fight against coronavirus: Scripps Research COVID-19 updates

Scripps Research

Novel Use of Rheum Drugs in COVID-19 (5.1.20)

Rituximab use in the COVID-19 era: Striking the right balance | Sebastian Sattui and David Jayne

Medicine Matters rheumatology

It is not clear if biologics and/or JAK inhibitors increase risk of Covid-19 infection.

Antiviral Treatments for COVID19 and Arthritis

AlbertaRheumatology

Study finds link between RA treatment and COVID-19 severity | Jeffrey Sparks and Zachary Wallace

Medicine Matters rheumatology

What about patients on biologics diagnosed with COVID-19, is the prognosis worse?

Crohn's and Colitis Canada

COVID-19 Update for Patients with Autoimmune Disease: Rheumatology Perspective

Emory Department of Medicine

ACR and COVID-19 Update: Our Response and Resources for You

American College of Rheumatology

Session 4 DMARD and Biologic Medication Update

Portsmouth Hospitals University NHS Trust

A Rheumatologist's message to immunosuppressed patients

Covid-19 and the use of antirheumatic drugs

Dr. Diana Girnita - Rheumatologist OnCall